Analyst Douglas Tsao of H.C. Wainwright maintained a Buy rating on Theravance Biopharma, retaining the price target of $20.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Douglas Tsao has given his Buy rating due to a combination of factors surrounding Theravance Biopharma’s development of ampreloxetine, a promising treatment for neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA). Dr. Horacio Kaufmann from NYU Langone Health expressed increased confidence in ampreloxetine’s potential to become the standard of care due to its unique feature of not causing supine hypertension, setting it apart from existing treatments.
Furthermore, the commercial prospects for ampreloxetine are significant, given the high unmet needs in the MSA patient population and the economics of rare diseases. The company is aligning its pricing strategy with other orphan drugs, which typically average around $300,000 annually. With the Phase 3 CYPRESS trial results anticipated in early 2026, a positive outcome could lead to a priority review and potential product launch by 2027, reinforcing the stock’s potential for growth.
Tsao covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Protagonist Therapeutics, and Hansa Biopharma AB. According to TipRanks, Tsao has an average return of 21.9% and a 55.15% success rate on recommended stocks.
In another report released on December 3, Oppenheimer also initiated coverage with a Buy rating on the stock with a $27.00 price target.